209 related articles for article (PubMed ID: 35955851)
21. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Alvarado MD; Prasad C; Rothney M; Cherbavaz DB; Sing AP; Baehner FL; Svedman C; Markopoulos CJ
Adv Ther; 2015 Dec; 32(12):1237-47. PubMed ID: 26610383
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
23. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
24. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
25. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
[TBL] [Abstract][Full Text] [Related]
26. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
27. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
28. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer.
Holm J; Yu NY; Johansson A; Ploner A; Hall P; Lindström LS; Czene K
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442660
[TBL] [Abstract][Full Text] [Related]
29. Prosigna test in breast cancer: real-life experience.
Hequet D; Harrissart G; Krief D; Maumy L; Lerebours F; Menet E; Callens C; Rouzier R
Breast Cancer Res Treat; 2021 Jul; 188(1):141-147. PubMed ID: 33860387
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic subtypes in Ethiopian breast cancer patient.
Desalegn Z; Yohannes M; Porsch M; Stückrath K; Anberber E; Santos P; Bauer M; Addissie A; Bekuretsion Y; Assefa M; Worku Y; Taylor L; Abebe T; Kantelhardt EJ; Vetter M
Breast Cancer Res Treat; 2022 Dec; 196(3):495-504. PubMed ID: 36282363
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
32. Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium.
Allott EH; Cohen SM; Geradts J; Sun X; Khoury T; Bshara W; Zirpoli GR; Miller CR; Hwang H; Thorne LB; O'Connor S; Tse CK; Bell MB; Hu Z; Li Y; Kirk EL; Bethea TN; Perou CM; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):470-8. PubMed ID: 26711328
[TBL] [Abstract][Full Text] [Related]
33. Advancing breast cancer subtyping: optimizing immunohistochemical staining classification with insights from real-world Taiwanese data.
Chang YT; Hong ZJ; Yu JC; Lin WZ; Huang TY; Tsai HH; Feng AC; Hsu KF; Huang CC; Chu CM; Liang CM; Liao GS
Am J Cancer Res; 2023; 13(11):5719-5732. PubMed ID: 38058819
[TBL] [Abstract][Full Text] [Related]
34. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
[TBL] [Abstract][Full Text] [Related]
35. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
[TBL] [Abstract][Full Text] [Related]
36. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
Prat A; Cheang MC; Martín M; Parker JS; Carrasco E; Caballero R; Tyldesley S; Gelmon K; Bernard PS; Nielsen TO; Perou CM
J Clin Oncol; 2013 Jan; 31(2):203-9. PubMed ID: 23233704
[TBL] [Abstract][Full Text] [Related]
38. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
Lundgren C; Bendahl PO; Borg Å; Ehinger A; Hegardt C; Larsson C; Loman N; Malmberg M; Olofsson H; Saal LH; Sjöblom T; Lindman H; Klintman M; Häkkinen J; Vallon-Christersson J; Fernö M; Rydén L; Ekholm M
Breast Cancer Res Treat; 2019 Nov; 178(2):459-467. PubMed ID: 31432367
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
[TBL] [Abstract][Full Text] [Related]
40. The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience.
Dank M; Mühl D; Pölhös A; Csanda R; Herold M; Kovacs AK; Madaras L; Kulka J; Palhazy T; Tokes AM; Toth M; Ujhelyi M; Szasz AM; Herold Z
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
